This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Herbert A. Fritsche, Ph.D., Former M.D. Anderson Cancer Center Professor And Scientist, Joins Health Discovery Corporation As Senior Vice President And Chief Science Officer

Health Discovery Corporation (OTCBB: HDVY) is pleased to announce that Herbert A. Fritsche, Ph.D., recently retired Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas, has joined Health Discovery Corporation as Senior Vice President and Chief Science Officer, effective September 1, 2010.

“We are extremely honored that Dr. Herbert Fritsche, one of the world’s leading experts on tumor biomarkers, with his vast and unique experience has agreed to become our Senior Vice President and Chief Science Officer," said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation.

"In addition to providing unparalleled scientific expertise, Dr. Fritsche will bring significant commercialization experience having been involved with every commercially available serum cancer biomarker currently in use in the United States," said Dr. Barnhill.

Dr. Fritsche was a co-author of the peer-reviewed publication of Health Discovery Corporation’s Four-Gene Expression Signature for Prostate Cancer Cells Consisting of UAP1, PDLIM5, IMPDH2, and HSPD1, in UroToday International Journal (August 2009).

As previously announced, Health Discovery Corporation entered into royalty-bearing licenses for the 4-gene urine-based prostate cancer test with Quest Diagnostics Incorporated (NYSE: DGX)  and Abbott Laboratories (NYSE: ABT) for development and commercialization. The Company also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test with Abbott Laboratories (NYSE: ABT) for development and commercialization.

“I’ve long believed that Dr. Barnhill and his patented pattern recognition technology are on the cutting edge of molecular diagnostic discovery and I’m delighted to join Dr. Barnhill and his world class team of mathematicians in new discovery projects,” said Dr. Fritsche. “This is a unique and a singular professional opportunity,” said Dr. Fritsche.

Dr. Fritsche continued, "I look forward to working with Dr. Barnhill and the distinguished group of world-renowned experts he has assembled to achieve the goal of advancing scientific discovery and commercializing the next generation of diagnostic markers and drug targets."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
HDVY $0.02 0.00%
AAPL $129.38 0.22%
FB $79.61 -0.18%
GOOG $573.65 0.40%
TSLA $199.54 1.10%


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs